Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis

被引：0
|
作者：
Schwarzer, A. [1 ]
Schulte, C. [2 ]
Fries, S. [3 ]
Cavo, M. [4 ]
Tsukada, N. [5 ]
Tekle, C. [6 ]
Manasanch, E. E. [7 ]
Knauf, W. [8 ]
机构：
[1] Onkopraxis Probstheida, Leipzig, Germany
[2] Gemeinsch Praxis Hamatol & Onkol, Dortmund, Germany
[3] Onkol Schwerpunktpraxis, Bamberg, Germany
[4] Univ Bologna, IRCCS Azienda Osped, Ist Ematol, Bologna, Italy
[5] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
[6] Sanofi, Cambridge, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[8] Centrum Hamatol & Onkol Bethanien, Frankfurt, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1109
引用
收藏
页码：316 / 316
页数：1
相关论文
共 50 条
  • [11] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [12] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study
    Leleu, Xavier
    Lafore, Radhia
    Iaquinta, Daniel
    Tekle, Christina
    Rice, Megan
    Decaux, Olivier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S176 - S177
  • [13] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [14] Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Maignan, Kathleen
    Backenroth, Daniel
    McQuarrie, Neil A.
    Lipitz, Nicole G.
    Williams, Erin R.
    Carson, Kenneth R.
    BLOOD, 2018, 132
  • [15] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
    Decaux, Olivier
    Fontan, Jean
    Perrot, Aurore
    Karlin, Lionel
    Touzeau, Cyrille
    Schulmann, Samantha
    Manier, Salomon
    Belhadj, Karim
    Trebouet, Adrien
    Zunic, Patricia
    Schiano De Colella, Jean-Marc
    Castel, Brice
    van de Wyngaert, Zoe
    Pica, Gian Matteo
    Tiab, Mourad
    Kuhnowski, Frederique
    Bouketouche, Malek
    Rigaudeau, Sophia
    Benramdane, Riad
    Tekle, Christina
    Lafore, Radhia
    Gaucher, Marianne
    Corre, Jill
    Leleu, Xavier
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (03) : 290 - 297
  • [16] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Kotowsky, Nirali
    Bitetti, Jacopo
    Mackay, Christine
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    BLOOD, 2022, 140 : 10124 - 10126
  • [17] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
  • [18] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moon, Joon-Ho
    Ng, Soo Chin
    Park, Sung Soo
    Koh, Youngil
    Lee, Ji Hyun
    Eom, Hyeon-Seok
    Shin, Ho-Jin
    Lee, Je-Jung
    Do, Young Rok
    Wilfred, Gilbert
    Husin, Azlan
    Kim, Hyo Jung
    Wahid, S. Fadilah Abdul
    Lee, Myung-Won
    Heo, Hye-won
    Kim, Kihyun
    Chuncharunee, Suporn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S264
  • [19] Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg
    De Wilde, Sigrid
    Plawny, Laurent
    Berchem, Guy
    HEMATOLOGY, 2023, 28 (01)
  • [20] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)
12345